EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Actinium Pharmaceuticals Inc (ATNM) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Actinium Pharmaceuticals Inc $0.17, price $1.17, upside -85.5%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US00507W2061

AP Actinium Pharmaceuticals Inc logo Thin data Sep 24, 2026

Actinium Pharmaceuticals Inc

ATNM · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.1700 · Strongly overvalued (−85.5%)
!Quality 36/100
!Weak Growth (revenue 5y −32.1 %/yr)
✓Highly profitable · 32.2% net margin (TTM)
!negative free cash flow
✓Ranks above peers (6/9)
✓Wide moat 75/100
!Evidence only low, so the estimate is less certain
Watch Actinium Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.41 $0.7490 Fair Value $0.1700 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.7490 – $14.41 · fair‑value band $0.1100 – $0.2200 · the $1.17 price screens above the $0.1700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Actinium Pharmaceuticals in your weekly email

Every Wednesday you see whether Actinium Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.

Show more

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Stock analysis

Actinium Pharmaceuticals Inc (ATNM) currently trades at $1.17, while our model-based Fair Value estimate is $0.1700, 85.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.1100 (bear) to $0.2200 (bull), the price of $1.17 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Actinium Pharmaceuticals Inc reported revenue of $90.0K in FY2025 versus $1.1M in FY2021, a compound −47.0%/yr. Reported net income was −$33.9M in FY2025.

Key figures

Market cap $44.0M · P/E ratio 3.3 · P/S ratio 1.25 · EPS (TTM) $0.3500 · Net margin 32.2% · Return on equity 45.9% · Return on assets (EBIT) −49.9% · Operating margin 78.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −85%, ATNM screens richer than that median.

Fair Value models

Bear $0.1100 Fair Value $0.1700 Bull $0.2200
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.2647 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.1200 $0.1700 $0.2500 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.1200 $0.1700 $0.2500 51

Open the full fair value analysis →

Notify me when ATNM reaches fair value

Put ATNM on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 36/100

Of which business quality 29 · Market factors (momentum, volatility) 42

Profitability 0
Margins and returns on capital today
Quality Growth 26
Are margins and returns improving?
Cashflow 5
Earnings quality: real cash, not paper profit
Fin. Strength 52
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 46
Price trend over the last 3–12 months (market factor)
52W Momentum 24
Distance to the 52-week high (market factor)
Net Issuance 48
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 9/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−55.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−32.1%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,600.2% (2020) → −40,274.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ATNM screens overvalued: fair value 85% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Actinium Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −85.2% · Bottom 25%
Profitability
Return on equity (TTM) 45.9% · Top 25%
Return on assets 11.6% · Top 25%
Net margin (TTM) 32.2% · Top 25%
Operating margin (TTM) 78.8% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 3.3× · Cheapest 25%
P/B 5.62× · Priciest 25%
P/S (TTM) 1.25× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Actinium Pharmaceuticals Inc · Fair Value
$0.1700 −85%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Actinium Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/ATNM

Frequently asked questions

Is Actinium Pharmaceuticals Inc (ATNM) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.1700 versus a price of $1.17, about −85% upside (overvalued).
What is the fair value of ATNM?
Our model-based fair value for Actinium Pharmaceuticals Inc is $0.1700 (as of Sep 24, 2026), built from audited fundamentals. The current price: $1.17.
What is the quality score of ATNM?
Actinium Pharmaceuticals Inc has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Actinium Pharmaceuticals Inc (ATNM)?
Our model-based price target is the fair value of $0.1700 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.1100, optimistic scenario $0.2200. It is a calculation from audited fundamentals, not an analyst target.
What is the Actinium Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $0.1700, about −85% upside versus a price of $1.17 (overvalued). Cautious scenario $0.1100, optimistic scenario $0.2200. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Actinium Pharmaceuticals Inc (ATNM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Actinium Pharmaceuticals Inc it is $0.1700 per share (as of Sep 24, 2026), against a price of $1.17. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Actinium Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ATNM trades above its calculated fair value: price $1.17, fair value $0.1700, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ATNM?
No. The price is what the market pays today ($1.17); the fair value is what the company's own numbers justify ($0.1700). For Actinium Pharmaceuticals Inc the two are $1.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Actinium Pharmaceuticals Inc worth?
The market values Actinium Pharmaceuticals Inc at about $44.0M (market capitalisation, as of Sep 24, 2026). Per share that is $1.17; our models calculate a fair value of $0.1700 per share.
What do the bullish and bearish scenarios say about ATNM?
Our models span a range for Actinium Pharmaceuticals Inc: cautious scenario $0.1100, base $0.1700, optimistic $0.2200 per share (as of Sep 24, 2026, price $1.17). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ATNM?
Actinium Pharmaceuticals Inc trades at a price-to-earnings ratio of 3.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.1700 is built from several models across several years. Other multiples: P/B 5.6, P/S 1.3.
How solid is the balance sheet of Actinium Pharmaceuticals Inc (ATNM)?
Balance-sheet figures for Actinium Pharmaceuticals Inc (as of Sep 24, 2026): return on equity 45.9%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is ATNM from its 52-week high?
Actinium Pharmaceuticals Inc trades at $1.17, about 31% below its 52-week high of $1.69 and 56% above the low of $0.7490 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1700 is for.
Which stocks are comparable to Actinium Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Actinium Pharmaceuticals Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $1.17, calculated fair value $0.1700 (−85%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ATNM calculated?
We run Actinium Pharmaceuticals Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Actinium Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Actinium Pharmaceuticals Inc (ATNM)?
The closing price on Oct 2, 2026 was $1.17. Our model-based fair value is $0.1700, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Actinium Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($0.2200). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1100 to $0.2200) leaves room in how you read the outcome.

Key figures of Actinium Pharmaceuticals Inc

How large is the market capitalisation of Actinium Pharmaceuticals Inc (ATNM)?
The market capitalisation of Actinium Pharmaceuticals Inc is $44.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Actinium Pharmaceuticals Inc (ATNM)?
The price-to-sales ratio of Actinium Pharmaceuticals Inc is 1.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Actinium Pharmaceuticals Inc (ATNM)?
Earnings per share at Actinium Pharmaceuticals Inc are $0.3500 (price ÷ EPS = P/E 3.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Actinium Pharmaceuticals Inc (ATNM)?
The net margin of Actinium Pharmaceuticals Inc is 32.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Actinium Pharmaceuticals Inc (ATNM)?
The return on equity (ROE) of Actinium Pharmaceuticals Inc is 45.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Actinium Pharmaceuticals Inc (ATNM)?
On an EBIT basis the return on assets of Actinium Pharmaceuticals Inc is −49.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Actinium Pharmaceuticals Inc (ATNM)?
The operating margin of Actinium Pharmaceuticals Inc is 78.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Actinium Pharmaceuticals Inc (ATNM) generate?
The free cash flow of Actinium Pharmaceuticals Inc is −$24.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Actinium Pharmaceuticals Inc (ATNM) hold?
Actinium Pharmaceuticals Inc holds more cash than debt, $46.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Actinium Pharmaceuticals Inc in the live analysis

One click puts Actinium Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.